The Derm-Approved System for Choosing Spot Treatment

A spot on the skin is a data point. The correct treatment follows from what type of data it is—lentigo, melasma, or PIH—and the skin’s Fitzpatrick phototype, which dictates how aggressively it produces pigment in response to insult. A systematic approach, not a marketing claim, separates protocols that clear the mark from those that leave a darker one. The derm-approved system for choosing spot treatment reduces to a three-step logic: identify the spot class and skin tone; eliminate modalities your skin will reject; then compare what remains to find the best functional fit. Everything else is noise.

The Two Variables That Dictate Every Treatment Decision

Spot origin determines depth and behavior. Lentigos are epidermal melanin deposits triggered by decades of UV; they stay put and don’t fluctuate with hormones. Melasma is a hormone–vascular–melanin interaction where pigment sits in both epidermis and dermis; heat and light reactivate it, making it a chronic, relapsing condition. PIH is trauma-induced melanin created at any depth where inflammation occurred—acne, a scrape, a peel too deep. Skin reactivity scales by Fitzpatrick type: types I–II have sparse melanocytes and low pigment-production capacity; types III–VI harbor increasingly active melanocytes that overproduce melanin when irritated. Pairing the wrong modality to this pair—say, a heat-driven device on melasma in type V skin—results in a net gain of pigment. Those two variables are non-negotiable inputs.

Step 1: Identify — Classify the Spot and Your Skin Phototype

Diagnostic clarity precedes treatment. A solar lentigo is a flat, sharply bordered brown or black patch, fixed in size, found on photo-exposed areas; it looks solid under magnification. Melasma appears as diffuse, muddy-brown or gray-brown patches with irregular borders, symmetrically patterned across the forehead, cheeks, and upper lip, worsening with heat and light. PIH is a flat mark that traces the outline of the original injury, ranging from pink to deep brown, and its depth matches the depth of the prior inflammation. These distinctions aren’t academic—they dictate which mechanism (melanin breakdown, melanin transfer inhibition, vascular suppression, or deep remodeling) a treatment must target.

Fitzpatrick phototype is equally concrete. The scale from I (always burns, never tans) to VI (deeply pigmented, never burns) can be approximated by one’s reaction to summer sun exposure without sunscreen. Underestimation is common: many people with type IV skin who tan easily and rarely burn classify themselves as II or III, and that misclassification opens the door to overly aggressive therapies. A correct identification yields two data points—single dominant spot class and a Fitzpatrick number—that become the lens for every subsequent filter.

Step 2: Eliminate — Cross Off Treatments That Carry Unacceptable Risk

This step applies a safety-first algorithm. The question isn’t “what treats this spot?” but “what can this skin tolerate while treating this spot?” For dark skin (Fitzpatrick IV–VI), any modality that provokes significant inflammation is a threat: high-fluence lasers, aggressive TCA peels, and dermabrasion can spawn fresh PIH that’s harder to clear than the original mark. For melasma, regardless of skin type, heat-based and high-energy devices—IPL, Q-switched lasers at standard fluence, ablative CO₂—are contraindicated because they fuel the vascular component and reactive pigment production. Even for lentigos on lighter skin, elimination considers contrast: cryotherapy can leave hypopigmented halos on type III–IV individuals, so it’s crossed off when that tradeoff is unacceptable.

This step also discards treatments that cannot physically reach the pigment. Superficial lactic acid peels won’t affect deep dermal melasma; a weak tyrosinase inhibitor alone won’t break apart dense lentigo melanosomes. The output is a shortlist of modalities that align with three constraints: the spot’s depth, the spot’s biological driver, and the skin’s inflammation-pigment threshold. For a lentigo on Fitzpatrick IV, that shortlist might include low-fluence Q-switched Nd:YAG, precise cryotherapy (with informed consent about hypopigmentation risk), or a medium-depth peel performed by a clinician who adjusts dwell time and concentration. For PIH on Fitzpatrick V, the list narrows to topical tyrosinase inhibitors, low-strength retinoids, time, and meticulous sun protection.

Step 3: Compare — Weigh the Remaining Options Head-to-Head

Valid options are compared on three axes: efficacy timeline, downtime, and compliance burden. Two approaches might both clear a lentigo on type III skin, but a single Q-switched laser session achieves clearance in roughly one week with scaling, while a 4% hydroquinone cream requires eight to twelve weeks of nightly application and strict UV avoidance—and carries a small but real risk of exogenous ochronosis if used beyond four months without breaks. The laser demands a higher upfront cost; the cream demands daily discipline. Neither is intrinsically better; the framework surfaces the tradeoff objectively.

Combination protocols also enter at this stage. Moderate melasma on type IV often shows the most consistent clearance with a compounded topical (hydroquinone–tretinoin–corticosteroid) combined with oral tranexamic acid and a daily mineral sunscreen routine. That regimen involves zero procedural recovery and yields gradual fading over 12–20 weeks. A series of low-fluence 1927 nm thulium fractional sessions could shorten the timeline to 8–12 weeks but adds procedural cost, requires still stricter sun avoidance, and carries a finite risk of rebound. The comparison surfaces the most logical starting point for the specific person’s risk tolerance, lifestyle, and budget. Done correctly, it turns a diffuse market of half-truths into a ranked, justifiable shortlist of one or two real contenders.

The Framework Applied: A Melasma Case on Fitzpatrick IV

A 34-year-old presents with symmetrical gray-brown patches across the mid-face—classic centrofacial melasma—and a phototype of IV (medium brown skin that tans deeply and rarely burns). Identification is straightforward: melasma, likely dermal–epidermal mixed. Elimination crosses off any IPL, high-fluence Q-switched laser, and medium-depth peels, all of which risk worsening the condition on this skin type. Also removed are standalone low-strength AHAs, which won’t reach the dermal component and may cause surface irritation. The remaining options: a triple-combination topical (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%), oral tranexamic acid (after medical clearance), and low-fluence 1927 nm non-ablative fractionated laser series. Comparison considers timelines and practical constraints: the topical is slow but fully controlled by the patient; the laser adds several sessions costing over a thousand dollars and requires aggressive sun avoidance; the oral agent is inexpensive but demands screening for thrombotic risk. The patient selects the topical plus oral route because it aligns with her budget and daily schedule, with a follow-up at week 12. The framework didn’t make the final choice—it eliminated the non-viable ones and made the remaining decision transparent.

Three Decisions That Derail the Process

Treating all dark spots as interchangeable. Over-the-counter “dark spot correctors” rarely distinguish between lentigo, PIH, and melasma. A high-concentration glycolic acid product might accelerate cell turnover enough to lighten an epidermal lentigo but can trigger an inflammatory cascade that deepens PIH on darker skin. Using a botanical tyrosinase inhibitor on dense sun-induced lentigos, which require physical melanin dispersion, wastes months with no mechanism to succeed. The penalty is twofold: financial loss and a widening window during which the underlying condition goes unaddressed and may worsen.

Comparing options before eliminating the dangerous ones. Algorithms in search results often surface treatment galleries without filtering for skin type. A search for “best dark spot laser” might prominently feature CO₂ fractional—effective for deep lentigos on type I–II skin, catastrophic for melasma on type IV–V. Jumping to comparison without elimination means the list itself is compromised, often containing exactly the modality that will cause the most damage. Elimination is the safety brake; bypassing it converts the entire exercise into a lottery.

Ignoring Fitzpatrick variability within a single spot category. Melasma in type II skin (light, burn-prone) behaves differently from melasma in type V (brown, heavily pigmented, highly vascular). Aggressive light-based treatments that work on type II often inflame and darken type V. The framework forces the question “melasma on what phototype?” before it permits the question “what’s the top melasma treatment?” Applying that rule prevents the most preventable and severe outcomes.

Quick Reference

Stage	Goal	Key Action
Identify	Pinpoint spot type and Fitzpatrick number	Use diagnostic criteria: border, distribution, color, history of sun/injurynGet dermoscopy if distinction is unclear
Eliminate	Remove treatments that risk worsening pigmentation	Cross off heat-based devices for melasma, high-fluence lasers and deep peels for darker skinnReject modalities that can’t reach the pigment depth
Compare	Select the best fit among safe options	Weigh downtime, cost, compliance requirement, and risk of recurrencenConsider combination protocols that stack mechanisms

FAQ

What if I have two types of spots at once—for example, lentigo and PIH?

Address the more reactive condition first. Stabilizing PIH requires anti-inflammatory measures and pigment-production inhibition; once the background inflammation quiets, the lentigo can be targeted without triggering new marks. Treating both simultaneously obscures cause and effect and amplifies risk.

Can I skip the Fitzpatrick typing if I’m only using over-the-counter topicals?

No. Even non-prescription ingredients have safety thresholds. Aggressive AHA exfoliants and high-strength physical scrubs provoke PIH on darker skin just as reliably as an ill-chosen laser. Hydroquinone, even OTC in some regions, carries an ochronosis risk that escalates with prolonged, unmonitored use.

How long should I wait between the elimination and comparison steps?

A 24-hour gap is useful. The elimination list can feel overly restrictive; evaluating the shortlist with a cooler perspective reduces the temptation to resurrect a crossed-off option that’s emotionally appealing but physiologically dangerous.

Is there a universally safe treatment?

No treatment carries zero risk for every spot and skin type. Broad-spectrum mineral sunscreen and strict sun avoidance are the only interventions that benefit all hyperpigmentation patterns without side effects—and they are prerequisites, not standalone solutions.

The Only Decision That Matters Today

The sequence—identify spot type and Fitzpatrick rating, eliminate what your skin cannot tolerate, compare what remains—turns an overwhelming field of products and procedures into a defensible shortlist. Begin with identification. Without a named spot and a verified phototype, every further step is guesswork. If you haven’t classified your spot yet, that is the only task that matters right now.